Alimentary/Metabolic
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.
Evaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.
The REDEFINE 2 study saw CagriSema fail to outshine Lilly’s tirzepatide in weight loss for overweight patients with diabetes, leaving its rival still in the driving seat.
Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.
Competing with two Phase III competitors in the FGF21 analog class, Boston Pharma is hoping to begin Phase III this year. Novo Nordisk poses a new challenge with zalfermin.
The five therapy areas forecast to achieve the highest growth between 2024 and 2030 include a mixture of the more obvious (MASH) and less high profile (glioma). In some cases, which companies will seize market share remains up for grabs.
With $180m in sales during its first nine months on the US market, the first approved MASH drug still tops projections. Madrigal predicts continued growth in 2025, with EU entry expected.
Deal snapshot: Organovo gets a needed infusion of cash with downstream potential for more, while Lilly may have obtained its second MASH candidate this month beyond its internal program with tirzepatide.
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
ASC30's Phase I study has produced the best-yet weight loss achieved by an oral drug at 28 days, and it could be a serious rival for Lilly’s frontrunner orforglipron.
Amylin analogs could well match the weight loss seen with Novo Nordisk and Eli Lilly’s GLP-1-based blockbusters with less fewer tolerability issues. The Danish company believes petrelintide will lead the pack and is vetting potential big pharma partners very carefully.
Two pharmaceutical companies reporting bumper sales in the hot areas of diabetes and obesity may have helped a thaw in sector sentiment.
Having built its portfolio from university collaborations and targeted in-licensing, the UK firm now hopes to validate its business model with Phase II readouts in 2025.
Patient demand for compounded versions of FDA-approved obesity drugs is unlikely to dissipate, even if semaglutide’s “shortage” status is resolved. The issue likely will continue to be a high-profile concern for the brand industry.
Large headcount reduction and ending preclinical programs may give Inventiva runway to report Phase III data for lanifibranor that are expected during the second half of 2026.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.